Advancing novel biologics that aim to offer the greatest possible freedom from disease to people with plaque psoriasis and other associated conditions
| Website | https://www.orukatx.com |
| Revenue | $5.7 million |
| Employees | 74 (52 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Biologics, Drug Development, Biotechnology, Targeted Therapy, Therapeutic Antibodies, Dermatology, Skin Disease Treatment, Psoriasis Research, Precision Medicine, Immunology, Pharmaceutical, Clinical Trials, Autoimmune Diseases, Inflammatory Diseases, Psoriatic Arthritis, Disease Treatment, Health |
| Competitors | Roche, Amgen, AstraZeneca, Novartis, Gilead Sciences, Vertex Pharmaceuticals, Biogen, Regeneron, Receptos, a wholly-owned subsidiary of Celgene, Lilly India +42 more (view full list) |
Looking for a particular Oruka Therapeutics employee's phone or email?
The Oruka Therapeutics annual revenue was $5.7 million in 2026.
Lawrence Klein is the CEO of Oruka Therapeutics.
52 people are employed at Oruka Therapeutics.